Stay updated on DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial
Sign up to get notified when there's something new on the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page.

Latest updates to the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page
- Check2 days agoChange DetectedThe site revision indicator in the footer changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe page now presents the NCT03782064 study record, including its terminated status, treatment and eligibility details, study results, and record dates. It also includes information about data sharing and links to the study protocol and statistical analysis plan.SummaryDifference53%

- Check16 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check30 days agoChange DetectedA site-wide NIH notice announces a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The footer revision label advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden message, replacing the study record content with an error page. This blocks access to the study details, contacts, and locations previously visible on the entry.SummaryDifference19%

Stay in the know with updates to DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page.